N,N-disubstituted diazocycloalkanes
AssigneeRecordati S.A.
InventorsAmedeo Leonardi, Gianni Motta, Carlo Riva, Rodolfo Testa
Life of this patent
Estimating the term…
Abstract
N,N-Disubstituted diazocycloalkanes of the formula I (R1=halogen, R2=(C3–C8)-cycloalkyl, R3=(C1–C4)-alkoxy or (C1–C4)-haloalkoxy group, m is 1 or 2 and n is 1 or 2, have affinity for serotonergic receptors. These compounds and their enantiomers, diastereoisomers, N-oxides, polymorphs, solvates and pharmaceutically acceptable salts are useful in the treatment of patients with neuromuscular dysfunction of the lower urinary tract and diseases related to 5-HT1A receptor.
Claims4
A compound having the general formula I
- wherein:
- R1 represents a halogen atom,
- R2 represents a (C3–C8)-cycloalkyl group,
- R3 represents a (C1–C4)-haloalkoxy group,
- m is 1 or 2, and
- n is 1,
- or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
A compound which is 1-[4-cyclohexyl-4-hydroxy-3-(2-fluorophenyl)-butyl]-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine or an N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof, in the form of any of its isolated stereoisomers
- 1-[(3R,4S)-4-cyclohexyl-4-hydroxy-3-(2-fluorophenyl)-butyl]-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine,
- 1-[(3S,4R)-4-cyclohexyl-4-hydroxy-3-(2-fluorophenyl)-butyl]-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine,
- 1-[(3R,4R)-4-cyclohexyl-4-hydroxy-3-(2-fluorophenyl)-butyl]-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine,
- 1-[(3S,4S)-4-cyclohexyl-4-hydroxy-3-(2-fluorophenyl)-butyl]-4-[2-(2,2,2-trifluoroethoxy)-phenyl]-piperazine,
- or a mixture of any two or more of the foregoing in any proportion.
A method for treating disorders of the urinary tract in a mammal in need thereof, comprising administering an effective amount of a compound having the general formula I
- wherein:
- R1 represents a halogen atom,
- R2 represents a (C3–C8)-cycloalkyl group,
- R3 represents a (C1–C4)-haloalkoxy group,
- m is 1 or 2, and
- n is 1 or 2,
- or an enantiomer, optical isomer, diastereomer, N-oxide, crystalline form, hydrate, or pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.